Articles

The combination of nivolumab plus docetaxel for NSCLC in the second-line setting improved overall survival, progression-free survival, and overall response rate, despite a slightly elevated risk of toxicity. Read More ›

Year in Review

Toripalimab versus Placebo in Combination with First-Line Chemotherapy for Advanced NSCLC without EGFR/ALK Mutations: CHOICE-01 Phase 3 Study

NSCLC IO 2022 - Midyear Review

First-line treatment of patients with advanced NSCLC with toripalimab plus chemotherapy resulted in improved progression-free survival and overall survival compared with chemotherapy alone. Read More ›

Year in Review

A Phase 3 Study of First-Line Sugemalimab versus Placebo plus Platinum-Based Chemotherapy for Patients with Metastatic NSCLC: GEMSTONE-302

NSCLC IO 2022 - Midyear Review

Sugemalimab plus chemotherapy resulted in statistically significant and clinically meaningful progression-free survival and overall survival improvement compared with placebo plus chemotherapy, regardless of tumor histology or PD-L1 expression level, in patients with newly diagnosed metastatic NSCLC. Read More ›

Wrap-Up

DESTINY-Breast04 Compared T-DXd with TPC in Patients with HER2-Low Breast Cancer

ASCO 2022 – Wrap-Up

DESTINY-Breast04 is the first trial comparing outcomes with trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients with HER2-low metastatic breast cancer treated with 1 or 2 prior lines of chemotherapy. Read More ›

Wrap-Up

TROPiCS-02 Primary Results: Sacituzumab Govitecan versus Treatment of Physician’s Choice in Patients with Advanced Breast Cancer

ASCO 2022 – Wrap-Up

The TROPiCS-02 study aims to confirm optimal treatment choice in patients with hormone receptor–positive/HER2-negative metastatic breast cancer whose disease progresses after having received endocrine therapy (ET) plus cyclin-dependent kinase (CDK)4/6 inhibitor. Read More ›

Wrap-Up

Ribociclib Efficacious in Patients with Unresectable or HR-Positive/HER2-Negative Metastatic Breast Cancer Receiving Fulvestrant or Exemestane After Not Responding to Prior Treatments

ASCO 2022 – Wrap-Up

Patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer who had previously advanced on any cyclin-dependent kinase (CDK)4/6 inhibitor plus any endocrine therapy (ET) showed a substantial progression-free survival (PFS) advantage in the ribociclib-treated cohort. Read More ›

Wrap-Up

Event-Free Survival by Residual Cancer Burden After Neoadjuvant Chemotherapy + Pembrolizumab for Early TNBC: KEYNOTE-522 Data

ASCO 2022 – Wrap-Up

Pembrolizumab plus chemotherapy increased event-free survival compared with chemotherapy alone, highlighting the relevance of neoadjuvant pembrolizumab therapy for improving survival in patients with early triple-negative breast cancer. Read More ›

Wrap-Up

Revised Overall Survival and Progression-Free Survival Data from the FAKTION Study: Capivasertib + Fulvestrant in Metastatic, ER-Positive Breast Cancer

ASCO 2022 – Wrap-Up

Capivasertib plus fulvestrant’s PFS advantage benefitted a broader patient population, and overall survival (OS) data with improved biomarker analyses can now be reported. Read More ›

Wrap-Up

Imlunestrant in ER-Positive Advanced Breast Cancer and Endometrial Endometrioid Cancer: EMBER Results

ASCO 2022 – Wrap-Up

Updated data from the EMBER trial of imlunestrant, a new oral selective estrogen receptor degrader showing sustained inhibition of estrogen receptor (ER)-dependent gene transcription and cell proliferation, have been released. Read More ›

Wrap-Up

Final Results from the Phase 3 ASCENT Study: Sacituzumab Govitecan versus TPC in Patients with Previously Treated, Metastatic TNBC

ASCO 2022 – Wrap-Up

Sacituzumab govitecan (SG) showed a significant survival benefit over single-agent chemotherapy treatment of physician’s choice (TPC) in the pivotal phase 3 ASCENT trial. Read More ›

Articles

Page 26 of 147